Perspective: the patient edition

Blue Latitude Health|8th April 2020

During the last decade, we have witnessed the rise of the empowered patient, who takes control over his or her health and is less reliant on healthcare professionals.

This has driven another trend – value-based care, which has caused pharmaceutical companies to move away from a product-centric approach and focus instead on patient outcomes.

In this issue of Perspective magazine, we explore how the industry can place a greater emphasis on patient-centricity, and how pharmaceutical companies are working with patients across the product lifecycle to develop therapies that better serve their unmet needs.

Download the magazine to learn:

• A patient’s view on how pharma can be more patient-centric

• Tips on patient engagement

• The importance of rational and emotional creative campaigns

• The ALS patient journey

• An article on CAR-T service design

• Thought provoking content on clinical trial access and the social determinants of healthcare, and on precision and personalised medicine.

 

If you would like to find out more about how we can help your brand to reach and engage with your customers in innovative ways, please get in touch with hello@bluelaitude.com

Delivering impactful customer engagements in COVID-19

Blue Latitude Health|14th July 2020

Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.

read more

Top 5 tips for a multi-indication product launch

Sana Rahim|8th July 2020

Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.

read more

If our patients are diverse, why are clinical trials so white?

Ling Song|22nd June 2020

Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.

read more